OLOGY URS

OLOGY URS At Ology, we focus on tailored services that best meet the needs of your company. Please send us a message or call us for an appointment.

Rather you are getting started or near the end of your clinical trial and you need additional resources, we are here to help push your team to the finish line.

05/14/2023

Happy Mother's Day to each of you from Ology! We ouldn't do this life without youi! We would like to extend a special shout out to one of the hardest working mother's we know. Sarah we love and appreciate you!

The benefits of (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsin...
05/11/2023

The benefits of (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS), according to real-world data from the CLASSIC-MS study. More than half of those who received the oral therapy in the clinical trials that supported its approval no longer needed further disease-modifying therapies (DMTs) and twice as many continued relapse-free over a median of 10.9 years compared with those never given it.

Read full article:
https://multiplesclerosisnewstoday.com/news-posts/2023/04/11/mavenclad-benefits-ms-sustained-up-15-years-after-last-treatment/

H. Lee Moffitt Cancer Center and Research Institute is enrolling 18 participants, 18 Years and older, for A First in Hum...
05/09/2023

H. Lee Moffitt Cancer Center and Research Institute is enrolling 18 participants, 18 Years and older, for A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV). The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease.
For more details about enrollment visit: https://clinicaltrials.gov/ct2/show/NCT05809752?recrs=a&draw=4&rank=26

Word Wednesday! ALL-CAUSE MORTALITY: A measure of all deaths, due to any cause, that occur during a clinical study. ...
05/03/2023

Word Wednesday!

ALL-CAUSE MORTALITY: A measure of all deaths, due to any cause, that occur during a clinical study.

Researchers are conducting what they call a first of its kind clinical trial to study how Hispanic and Black patients re...
04/27/2023

Researchers are conducting what they call a first of its kind clinical trial to study how Hispanic and Black patients respond to a common medication for multiple sclerosis.
About 30% of people with MS in the United States are Black and Latino Americans, but they make up less than 5% of MS clinical trials participants, according to neurologist Mitzi Joi Williams, who is leading the new research.
What they're saying: "We hope to identify more insights into the unique nature of MS in these underrepresented populations so we can ultimately ensure we’re providing individuals with the best possible personalized care," Williams told Axios Latino.

Read more about this trial at: https://www.axios.com/2023/04/11/multiple-sclerosis-latino-black-american-health

WORD WEDNESDAY!RANDOMIZED ALLOCATION: A type of allocation strategy in which participants are assigned to the arms of a ...
04/26/2023

WORD WEDNESDAY!

RANDOMIZED ALLOCATION: A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

Word Wednesday! ACCPETS HEALTHY VOLUNTEERS: A type of eligibility criteria that indicates whether people who do not have...
04/19/2023

Word Wednesday!

ACCPETS HEALTHY VOLUNTEERS: A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in the clinical study.

Merck & Co – known as MSD outside the US and Canada – and Proxygen have entered into a multi-year research collaboratio...
04/14/2023

Merck & Co – known as MSD outside the US and Canada – and Proxygen have entered into a multi-year research collaboration and licensing agreement to jointly identify molecular glue degraders against multiple undisclosed therapeutic targets.
Under the terms of the agreement, the Austrian biotech will receive an upfront payment from Merck and will be eligible for future payments of up to $2.55bn plus royalties. The deals are based on Proxygen’s platform technology and capabilities in identifying novel molecular glue degraders, which are designed to reprogramme the cell’s natural recycling machinery to selectively eliminate disease-causing proteins.
Click on one of the links to read more.

https://www.linkedin.com/posts/pharmemed_merck-and-proxygen-partner-in-deal-worth-activity-7049722308243922944-xXoq?utm_source=share&utm_medium=member_desktop

https://www.pmlive.com/pharma_news/merck_and_proxygen_partner_in_deal_worth_up_to_$2.5bn_1490455

Address

Irvine, CA

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+19494316624

Website

Alerts

Be the first to know and let us send you an email when OLOGY URS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to OLOGY URS:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category